Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1 The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following Ulonivirine Administration
Timeframe: Baseline and up to approximately 24 hours
Plasma Concentration of Ulonivirine at QTc Intervals (Cqtc)
Timeframe: At designated timepoints (up to approximately 24 hours)